- AGC Biologics has expanded its long-term manufacturing agreement with a global pharmaceutical company, adding its Copenhagen facility as a second supply node alongside its existing Yokohama site. The total value of the agreement now exceeds €500 million.
- The expanded agreement covers six biologics programs at the Copenhagen facility, including process transfer, scale-up, validation and commercial production.
AGC Biologics has expanded its long-term manufacturing agreement with a global pharmaceutical company, adding its Copenhagen facility in Denmark as a second supply node alongside its existing manufacturing operations in Yokohama, Japan. The expanded agreement increases the total deal value to more than €500 million.
The agreement covers multi-product drug substance manufacturing across six biologics programs at the Copenhagen site. The scope includes process transfer, scale-up, validation and commercial production. Products will launch and move between facilities, with several dual regulatory submissions planned to support capacity optimization, cost considerations and local manufacturing benefits.
The two-site arrangement is designed to provide greater supply chain flexibility and resilience than a single-site manufacturing model. According to AGC Biologics, the expanded partnership builds on its experience supporting cross-site product launches. Two existing customers have already chosen to co-launch products from its Seattle and Copenhagen facilities.
“This customer is building a more resilient, more flexible supply chain, and they’ve chosen to do that with us across two continents. The agreement reflects demand for geographic flexibility and regionalized manufacturing while maintaining global supply.”
Alberto Santostagino, President and CEO of AGC Biologics
The expansion follows an earlier agreement covering five programs at AGC Biologics’ Yokohama site. Tadashi Murano, President of AGC Life Science Company, said the customer’s decision to bring six additional programs to Copenhagen reflects the trust built across the company’s manufacturing network.
